Contrast agent-free functional magnetic resonance imaging with matrix pencil decomposition to quantify abnormalities in lung perfusion and ventilation in patients with cystic fibrosis.

Background

Previous studies showed that contrast-enhanced (CE) morpho-functional magnetic resonance imaging (MRI) detects abnormalities in lung morphology and perfusion in patients with cystic fibrosis (CF). Novel matrix pencil decomposition MRI (MP-MRI) enables quantification of lung perfusion and ventilation without intravenous contrast agent administration.

Objectives

To compare MP-MRI with established morpho-functional MRI and spirometry in patients with CF.

Methods

Thirty-nine clinically stable patients with CF (mean age 21.6 ± 10.7 years, range 8-45 years) prospectively underwent morpho-functional MRI including CE perfusion MRI, MP-MRI and spirometry. Two blinded chest radiologists assessed morpho-functional MRI and MP-MRI employing the validated chest MRI score. In addition, MP-MRI data were processed by automated software calculating perfusion defect percentage (QDP) and ventilation defect percentage (VDP).

Results

MP perfusion score and QDP correlated strongly with the CE perfusion score (both

Conclusion

MP-MRI detects abnormalities in lung perfusion and ventilation in patients with CF without intravenous or inhaled contrast agent application, and correlates strongly with the well-established CE perfusion MRI score and spirometry. Automated analysis of MP-MRI may serve as quantitative noninvasive outcome measure for diagnostic monitoring and clinical trials.

Informations de copyright

Copyright © 2024 Doellinger, Bauman, Roehmel, Stahl, Posch, Steffen, Pusterla, Bieri, Wielpütz and Mall.

Déclaration de conflit d'intérêts

MS reports research grants from the German Federal Ministry of Education and Research (BMBF), the German Research Foundation (DFG) and Vertex Pharmaceuticals paid to the institution; personal fees for participation in advisory boards or consulting from Vertex Pharmaceuticals. MW reports research grants from Vertex Pharmaceuticals paid to the institution; consulting fees from Boehringer Ingelheim and Vertex Pharmaceuticals paid to the institution; lecture fees from Vertex Pharmaceuticals paid to the institution. MM reports research grants from the German Federal Ministry of Education and Research (BMBF), the German Research Foundation (DFG) and Vertex Pharmaceuticals paid to the institution; personal fees for participation in advisory boards or consulting from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotech, Vertex Pharmaceuticals; lecture fees from Vertex Pharmaceuticals; and travel reimbursement from Boehringer Ingelheim and Vertex Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.